Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Blood. 2012 Jul 12;120(2):347-55. doi: 10.1182/blood-2011-07-369397. Epub 2012 May 30.
TGF-β-activated kinase 1 (TAK1), a member of the MAPK kinase family, plays a key role in B-cell growth and development. In the present study, we examined the potential role of TAK1 as a therapeutic target for lymphoma. Here, we show that the active phosphorylated form of TAK1 is abundantly expressed in a panel of lymphoma cell lines, including mantle cell, anaplastic large cell, and Hodgkin lymphoma cell lines. Silencing TAK1 expression via the use of siRNA inhibited the activation of NF-κB and p38 and induced apoptosis in lymphoma cell lines. Moreover, submicromolar concentrations of AZ-TAK1, a novel ATP-competitive small molecule inhibitor of TAK1, dephosphorylated TAK1, p38, and IκB-α in lymphoma cell lines. These molecular events were associated with the release of cytochrome c into the cytosol, down-regulation of X-linked inhibitor of apoptosis, activation of caspase 9, and induction of apoptosis. We also demonstrate that primary lymphoma cells express TAK1 and pTAK1 and were sensitive to AZ-TAK1-mediated cell death. Collectively, our data demonstrate an essential role for TAK1 in regulating critical survival mechanisms in lymphoma and suggest that it may serve as a therapeutic target.
转化生长因子-β激活激酶 1(TAK1)是丝裂原活化蛋白激酶激酶家族的成员,在 B 细胞的生长和发育中发挥关键作用。在本研究中,我们研究了 TAK1 作为淋巴瘤治疗靶点的潜力。结果显示,在一系列淋巴瘤细胞系中,包括套细胞淋巴瘤、间变大细胞淋巴瘤和霍奇金淋巴瘤细胞系中,TAK1 的活性磷酸化形式大量表达。通过使用 siRNA 沉默 TAK1 的表达,抑制了 NF-κB 和 p38 的激活,并诱导了淋巴瘤细胞系的凋亡。此外,新型 TAK1 的小分子抑制剂 AZ-TAK1 以亚微摩尔浓度抑制了 TAK1、p38 和 IκB-α 的磷酸化。这些分子事件与细胞色素 c 向细胞质中的释放、凋亡抑制蛋白 X 连锁的下调、半胱天冬酶 9 的激活以及凋亡的诱导有关。我们还证明原发性淋巴瘤细胞表达 TAK1 和 pTAK1,并且对 AZ-TAK1 介导的细胞死亡敏感。综上所述,我们的数据表明 TAK1 在调节淋巴瘤中关键生存机制方面发挥着重要作用,并提示其可能成为治疗靶点。